Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2021-01-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于通过高新技术企业重新认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the company's successful re-certification as a high-tech enterprise, including details about tax benefits and certificate validity. It does not contain financial statements, detailed financial data, or comprehensive report content. The length is only 619 characters, and it serves as a formal notification rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-01-18 Chinese
关于控股子公司华兰生物疫苗股份有限公司首次公开发行股票并在创业板上市申请获深圳证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (711 characters) regarding the acceptance by the Shenzhen Stock Exchange of the application for the initial public offering (IPO) and listing of a controlling subsidiary. It states that the application materials have been accepted and that further approvals are pending, with a caution about investment risks. There is no detailed financial data, no full report, and the document is primarily an update on a capital market transaction process. This fits the category of Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement since it does not mention a report being published or attached, nor is it a regulatory filing or other category. Therefore, the best classification is CAP with high confidence.
2020-12-03 Chinese
关于部分高管减持股份计划期限届满的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the expiration of a share reduction plan by certain senior executives of the company. It details the number of shares reduced, the methods of reduction, and the shareholding changes before and after the reduction. It references compliance with securities laws and stock exchange rules related to shareholding by directors and senior management. There is no indication of financial statements, earnings data, or management discussion of financial results. The content focuses on insider share transactions by company directors and executives. Therefore, this document fits the category of Director's Dealing (DIRS). The document length is about 3,084 characters, which is consistent with a detailed announcement rather than a full report or a brief notice.
2020-11-06 Chinese
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 年第三季度报告全文" which translates to "2020 Third Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, and management commentary on financial performance and significant events during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (third quarter) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-10-30 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow, and other financial indicators for the third quarter of 2020. The document also includes management's discussion on financial changes, shareholder information, and other operational details relevant to the quarter. The length of the document (7264 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-10-30 Chinese
关于公司取得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the receipt of a drug clinical trial approval notice from the national drug regulatory authority. It includes risk warnings and information about the clinical trial process and its impact on company performance. The document is short (875 characters) and serves as an official notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed regulatory filings beyond the announcement itself. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-09-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.